AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
NVDA   408.64 (+3.49%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
GE   6.86 (+1.48%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
T   30.46 (+0.46%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
NFLX   502.78 (+1.95%)
BA   180.08 (+0.67%)
Log in

NASDAQ:CMTAClementia Pharmaceuticals Competitors & Alternatives

Notice: This company has been marked as potentially delisted and may not be actively trading.
$26.35
0.00 (0.00 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$26.35
Now: $26.35
$26.35
50-Day Range
$26.35
MA: $26.35
$26.35
52-Week Range
$8.10
Now: $26.35
$26.73
VolumeN/A
Average Volume145,059 shs
Market Capitalization$1.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.64

Competitors

Clementia Pharmaceuticals (NASDAQ:CMTA) Vs. GWPH, HCM, AGIO, FGEN, CCXI, and BBIO

Should you be buying CMTA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Clementia Pharmaceuticals, including GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), FibroGen (FGEN), ChemoCentryx (CCXI), and BridgeBio Pharma (BBIO).

Clementia Pharmaceuticals (NASDAQ:CMTA) and GW Pharmaceuticals PLC- (NASDAQ:GWPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility & Risk

Clementia Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, GW Pharmaceuticals PLC- has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Clementia Pharmaceuticals and GW Pharmaceuticals PLC-, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clementia Pharmaceuticals0000N/A
GW Pharmaceuticals PLC-001103.00

GW Pharmaceuticals PLC- has a consensus price target of $187.7273, indicating a potential upside of 45.53%. Given GW Pharmaceuticals PLC-'s higher probable upside, analysts clearly believe GW Pharmaceuticals PLC- is more favorable than Clementia Pharmaceuticals.

Insider & Institutional Ownership

78.7% of Clementia Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.8% of GW Pharmaceuticals PLC- shares are owned by institutional investors. 3.1% of GW Pharmaceuticals PLC- shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Clementia Pharmaceuticals and GW Pharmaceuticals PLC-'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clementia PharmaceuticalsN/A-44.73%-41.66%
GW Pharmaceuticals PLC-8.42%-9.87%-8.32%

Valuation and Earnings

This table compares Clementia Pharmaceuticals and GW Pharmaceuticals PLC-'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clementia PharmaceuticalsN/AN/A$-58,130,000.00($7.93)-3.32
GW Pharmaceuticals PLC-$311.33 million12.86$-9,020,000.00($0.24)-537.50

GW Pharmaceuticals PLC- has higher revenue and earnings than Clementia Pharmaceuticals. GW Pharmaceuticals PLC- is trading at a lower price-to-earnings ratio than Clementia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

GW Pharmaceuticals PLC- beats Clementia Pharmaceuticals on 12 of the 12 factors compared between the two stocks.

Clementia Pharmaceuticals (NASDAQ:CMTA) and HUTCHISON CHINA/S (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Valuation and Earnings

This table compares Clementia Pharmaceuticals and HUTCHISON CHINA/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clementia PharmaceuticalsN/AN/A$-58,130,000.00($7.93)-3.32
HUTCHISON CHINA/S$204.89 million19.06$-106,020,000.00($0.80)-36.60

Clementia Pharmaceuticals has higher earnings, but lower revenue than HUTCHISON CHINA/S. HUTCHISON CHINA/S is trading at a lower price-to-earnings ratio than Clementia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Clementia Pharmaceuticals and HUTCHISON CHINA/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clementia Pharmaceuticals0000N/A
HUTCHISON CHINA/S00403.00

HUTCHISON CHINA/S has a consensus price target of $29.00, indicating a potential downside of 0.96%. Given HUTCHISON CHINA/S's higher probable upside, analysts clearly believe HUTCHISON CHINA/S is more favorable than Clementia Pharmaceuticals.

Volatility & Risk

Clementia Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, HUTCHISON CHINA/S has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Profitability

This table compares Clementia Pharmaceuticals and HUTCHISON CHINA/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clementia PharmaceuticalsN/A-44.73%-41.66%
HUTCHISON CHINA/SN/AN/AN/A

Insider & Institutional Ownership

78.7% of Clementia Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.9% of HUTCHISON CHINA/S shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

HUTCHISON CHINA/S beats Clementia Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Agios Pharmaceuticals (NASDAQ:AGIO) and Clementia Pharmaceuticals (NASDAQ:CMTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares Agios Pharmaceuticals and Clementia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agios Pharmaceuticals$117.91 million32.05$-411,470,000.00($6.86)-8.00
Clementia PharmaceuticalsN/AN/A$-58,130,000.00($7.93)-3.32

Clementia Pharmaceuticals has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Clementia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Agios Pharmaceuticals and Clementia Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Agios Pharmaceuticals021202.86
Clementia Pharmaceuticals0000N/A

Agios Pharmaceuticals currently has a consensus target price of $69.6667, indicating a potential upside of 26.99%. Given Agios Pharmaceuticals' higher probable upside, equities research analysts plainly believe Agios Pharmaceuticals is more favorable than Clementia Pharmaceuticals.

Volatility and Risk

Agios Pharmaceuticals has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Clementia Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Profitability

This table compares Agios Pharmaceuticals and Clementia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Agios Pharmaceuticals-205.20%-63.85%-45.21%
Clementia PharmaceuticalsN/A-44.73%-41.66%

Insider & Institutional Ownership

97.7% of Agios Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.7% of Clementia Pharmaceuticals shares are owned by institutional investors. 3.2% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Agios Pharmaceuticals beats Clementia Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and Clementia Pharmaceuticals (NASDAQ:CMTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares FibroGen and Clementia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroGen$256.58 million14.55$-76,970,000.00($0.89)-47.09
Clementia PharmaceuticalsN/AN/A$-58,130,000.00($7.93)-3.32

Clementia Pharmaceuticals has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Clementia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for FibroGen and Clementia Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FibroGen02302.60
Clementia Pharmaceuticals0000N/A

FibroGen currently has a consensus target price of $57.60, indicating a potential upside of 37.44%. Given FibroGen's higher probable upside, equities research analysts plainly believe FibroGen is more favorable than Clementia Pharmaceuticals.

Volatility and Risk

FibroGen has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Clementia Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Profitability

This table compares FibroGen and Clementia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FibroGen-42.75%-19.32%-12.59%
Clementia PharmaceuticalsN/A-44.73%-41.66%

Insider & Institutional Ownership

71.7% of FibroGen shares are owned by institutional investors. Comparatively, 78.7% of Clementia Pharmaceuticals shares are owned by institutional investors. 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

FibroGen beats Clementia Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Clementia Pharmaceuticals (NASDAQ:CMTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares ChemoCentryx and Clementia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$36.13 million105.61$-55,490,000.00($0.98)-62.95
Clementia PharmaceuticalsN/AN/A$-58,130,000.00($7.93)-3.32

ChemoCentryx has higher revenue and earnings than Clementia Pharmaceuticals. ChemoCentryx is trading at a lower price-to-earnings ratio than Clementia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ChemoCentryx and Clementia Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx00813.11
Clementia Pharmaceuticals0000N/A

ChemoCentryx currently has a consensus target price of $70.1111, indicating a potential upside of 13.65%. Given ChemoCentryx's higher probable upside, equities research analysts plainly believe ChemoCentryx is more favorable than Clementia Pharmaceuticals.

Volatility and Risk

ChemoCentryx has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Clementia Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Profitability

This table compares ChemoCentryx and Clementia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-192.93%-100.55%-30.75%
Clementia PharmaceuticalsN/A-44.73%-41.66%

Insider & Institutional Ownership

70.0% of ChemoCentryx shares are owned by institutional investors. Comparatively, 78.7% of Clementia Pharmaceuticals shares are owned by institutional investors. 9.3% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ChemoCentryx beats Clementia Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

BridgeBio Pharma (NASDAQ:BBIO) and Clementia Pharmaceuticals (NASDAQ:CMTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Insider & Institutional Ownership

92.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 78.7% of Clementia Pharmaceuticals shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BridgeBio Pharma and Clementia Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$40.56 million91.03$-260,590,000.00($2.48)-12.27
Clementia PharmaceuticalsN/AN/A$-58,130,000.00($7.93)-3.32

Clementia Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Clementia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BridgeBio Pharma and Clementia Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BridgeBio PharmaN/AN/AN/A
Clementia PharmaceuticalsN/A-44.73%-41.66%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BridgeBio Pharma and Clementia Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BridgeBio Pharma111002.75
Clementia Pharmaceuticals0000N/A

BridgeBio Pharma currently has a consensus target price of $44.4545, indicating a potential upside of 46.14%. Given BridgeBio Pharma's higher probable upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Clementia Pharmaceuticals.

Summary

BridgeBio Pharma beats Clementia Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GW Pharmaceuticals PLC- logo
GWPH
GW Pharmaceuticals PLC-
1.6$129.00flat$4.00 billion$311.33 million131.63Insider Selling
HUTCHISON CHINA/S logo
HCM
HUTCHISON CHINA/S
1.0$29.28flat$3.81 billion$204.89 million-36.60
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$54.86flat$3.78 billion$117.91 million-9.35
FibroGen logo
FGEN
FibroGen
2.1$41.91flat$3.71 billion$256.58 million-31.75
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$61.69flat$3.64 billion$36.13 million-56.60Insider Selling
Unusual Options Activity
BBIO
BridgeBio Pharma
1.6$30.42flat$3.60 billion$40.56 million-12.27Insider Selling
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$57.07flat$3.54 billion$306.98 million-11.44Insider Selling
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.80flat$3.24 billion$806.43 million-9.88
Allakos logo
ALLK
Allakos
1.1$68.86flat$3.24 billionN/A-34.60Analyst Downgrade
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
2.2$83.88flat$3.13 billionN/A-32.77Heavy News Reporting
Alkermes logo
ALKS
Alkermes
1.1$20.41flat$3.12 billion$1.17 billion-23.19
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.5$56.80flat$3.08 billion$25 million-12.59Analyst Downgrade
Insider Selling
Increase in Short Interest
Heavy News Reporting
Insmed logo
INSM
Insmed
1.5$28.39flat$2.90 billion$136.47 million-10.07Analyst Upgrade
KRTX
Karuna Therapeutics
1.5$100.18flat$2.64 billionN/A-0.68Increase in Short Interest
Opko Health logo
OPK
Opko Health
1.7$4.08flat$2.63 billion$901.90 million-8.50Analyst Report
Increase in Short Interest
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$65.81flat$2.61 billion$644.77 million10.35Decrease in Short Interest
Amarin logo
AMRN
Amarin
1.8$6.77flat$2.59 billion$429.76 million-112.83
TG Therapeutics logo
TGTX
TG Therapeutics
1.7$23.86flat$2.49 billion$150,000.00-11.75Analyst Downgrade
Heavy News Reporting
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.7$30.97flat$2.33 billionN/A-4.93Increase in Short Interest
Heavy News Reporting
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$56.54flat$2.29 billion$421.03 million-2,825.59Analyst Report
TPTX
Turning Point Therapeutics
1.4$61.85flat$2.25 billionN/A-17.18
SAGE Therapeutics logo
SAGE
SAGE Therapeutics
1.6$44.40flat$2.20 billion$6.87 million-3.57Heavy News Reporting
IGMS
IGM Biosciences
1.5$72.17flat$2.17 billionN/A-15.04Analyst Downgrade
Uniqure logo
QURE
Uniqure
1.7$46.82flat$1.99 billion$7.28 million-15.55Analyst Downgrade
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.1$16.84flat$1.91 billion$306.49 million19.14
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.7$25.74flat$1.91 billion$23.90 million-15.23Insider Selling
Decrease in Short Interest
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$49.24flat$1.88 billion$26.69 million-37.30Analyst Upgrade
Heavy News Reporting
Principia Biopharma logo
PRNB
Principia Biopharma
1.4$56.38flat$1.88 billion$35.16 million-23.11Analyst Report
Xencor logo
XNCR
Xencor
1.6$32.95flat$1.87 billion$156.70 million-30.79Heavy News Reporting
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.8$36.24flat$1.82 billion$963.01 million13.04Increase in Short Interest
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$111.97flat$1.77 billion$120.28 million-32.55Analyst Downgrade
Unusual Options Activity
Heavy News Reporting
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$15.61flat$1.74 billion$320,000.00-11.92Analyst Downgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.9$19.34flat$1.74 billionN/A-5.74Analyst Report
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.5$13.03flat$1.73 billion$335 million-5.90Analyst Upgrade
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.3$41.60flat$1.70 billionN/A-16.71
Zymeworks logo
ZYME
Zymeworks
1.7$37.28flat$1.69 billion$29.54 million-9.58Increase in Short Interest
Heavy News Reporting
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$110.00flat$1.69 billionN/A-16.15Analyst Downgrade
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.5$25.05flat$1.64 billion$60,000.00-9.01Analyst Downgrade
Unusual Options Activity
Heavy News Reporting
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.16flat$1.64 billion$428.41 million19.17Analyst Downgrade
Heavy News Reporting
Epizyme logo
EPZM
Epizyme
1.6$16.25flat$1.60 billion$23.80 million-8.00Analyst Downgrade
ZNTL
Passage Bio
1.1$42.54flat$1.58 billionN/A0.00
IMAB
I-Mab
1.2$29.50flat$1.57 billion$4.31 million-1.02Heavy News Reporting
Cytokinetics logo
CYTK
Cytokinetics
1.4$26.92flat$1.55 billion$26.87 million-12.02Analyst Upgrade
Insider Selling
Decrease in Short Interest
Heavy News Reporting
MacroGenics logo
MGNX
MacroGenics
1.3$31.51flat$1.53 billion$64.19 million-10.20Increase in Short Interest
Zogenix logo
ZGNX
Zogenix
2.0$27.58flat$1.53 billion$3.65 million-2.92
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$22.85flat$1.49 billion$42.12 million-16.32
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$44.05flat$1.48 billion$252 million-4.11
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.3$26.08flat$1.47 billion$410,000.00-6.59Analyst Upgrade
ZEALAND PHARMA/S logo
ZEAL
ZEALAND PHARMA/S
0.8$36.96flat$1.47 billion$6.20 million-13.69
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.8$19.48flat$1.43 billion$40.89 million-6.67
This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.